CliffBio
small molecule

AZOR

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZOR
Active ingredientAMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL
StrengthEQ 10MG BASE;40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2007
Marketing statusRX

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.